Tumor-infiltrating lymphocytes are biomarkers of the tumor microenvironment’s dynamics and a patient’s intrinsic anti-tumor immunity.
A deeper molecular understanding of systemic sclerosis will likely usher in tailored treatment strategies, potentially combining multiple targeted therapies to address immune abnormalities.
11th of November, 2024
Learn more12th of November, 2024
Learn more13th of November, 2024
Learn more14th of November, 2024
Learn moreThis website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settings